Auron Therapeutics Secures $27M in Series B to Transform the Future of Oncology

Auron Therapeutics, Inc. is thrilled to announce a significant milestone in our journey as a leader in cell state targeting for oncology. We have successfully raised $27,000,000 in a recent funding round, which is poised to accelerate our mission of delivering novel therapies to patients battling both solid tumors and hematological malignancies. As a privately held, patient-centered, platform-powered, and product-driven oncology company, we remain steadfast in our commitment to innovative treatment approaches that address unmet clinical needs. This new funding will drive the continued development of our proprietary approach to identifying and targeting unique cellular states that contribute to the persistence and progression of cancer. By leveraging our state-of-the-art research and advanced platform, we intend to expand our portfolio of promising candidates in clinical and preclinical development, ensuring that our therapies are at the forefront of personalized and precision medicine. The infusion of capital not only enables us to enhance our research capabilities but also strengthens our collaborations with leading academic institutions and industry partners. This strategic investment further solidifies our commitment to improving patient outcomes worldwide and accelerating the translation of groundbreaking discoveries into tangible therapeutic solutions. As we embark on this exciting new chapter, our dedicated team of scientists, clinicians, and industry experts is more motivated than ever to push the boundaries of what is possible in oncology. We extend our deepest gratitude to our investors, partners, and the patient communities we serve for believing in our vision and joining us on this transformative journey.